Study of Histopathology of Rat Liver under the Effects of Dexmedetomidine during Experimental Sepsis

Authors

  • Shamsa Mohsin Avicenna Medical & Dental College, Lahore
  • Fatima Inam Akhtar Saeed Medical & Dental College, Lahore
  • Munazza Sardar Allama Iqbal Medical College, Lahore.
  • Nadia Majeed Abu umara medical & dental college
  • Humaira Gul Independent medical college , Faisalabad
  • Rukhsana Jabeen Niazi Medical College, Sargodha

DOI:

https://doi.org/10.47489/szmc.v38i3.534

Keywords:

Dexmedetomidine, Antidepressant, sepsis

Abstract

Introduction: The Food and Drug Administration Authority has approved a new antidepressant dexmedetomidine for use in critical care units. Dexmedetomidine is an imidazole compound with a high affinity for alpha-2 adrenoceptors, known for its anti-anxiety effect and minimal respiratory difficulty. Patients admitted to critical care units need prolonged sedation and require agents like dexmedetomidine. The leading cause of death in hospitals is sepsis which is a disorder resulting from the response of the host to infectious substances.

Aims and Objectives: The aim of the study is to identify the histopathological changes in rat liver on administering dexmedetomidine during septicemia.

Place and Duration of study: The study was conducted in the animal house of the Postgraduate Medical Institute, Lahore over 4 weeks.

Material and Methods: Ethical approval was obtained from the Ethical Committee at Postgraduate Medical Institute, Lahore. Female rats weighing 200-250 grams were taken for 4 weeks. One week before the experiment, animals were adapted in the lab maintained at 22 ± 2°C, with a continuous 12-hour light/dark cycle.. Data was entered and analyzed using SPSS version 25. P value of < 0.05 was considered statistically significant.

Results: The control group did not show any significant changes. Three mortalities were observed in the toxic groups Total scoring of pathological alterations in the liver was done. The hepatic tissue scoring of the control group was 0.4±0.52. In the septic group, it was 1.5±0.80 & in the dexmedetomidine groups it was 4.5±0.9. The differences in variations of tissues were statistically significant.

Conclusion: The study concludes that dexmedetomidine induces beneficial changes in the histopathology of rat liver during sepsis.

References

Huang YQ, Wen RT, Li XT, Zhang J, Yu ZY, Feng YF. The protective effect of dexmedetomidine against ischemia-reperfusion injury after hepatectomy: a meta-analysis of randomized controlled trials. Front Pharmacol. 2021 Oct 12;12:747911.

Bao N, Tang B. Organ-protective effects and the underlying mechanism of dexmedetomidine. Mediators Inflamm. 2020;2020:6136105.

Arslan M. Effect of dexmedetomidine on ischemia-reperfusion injury of liver and kidney tissues in experimental diabetes and hepatic ischemia-reperfusion injury induced rats. Anaesth Pain Intensive Care. 2019 May 13.

Chen R, Dou XK, Dai MS, Sun Y, Sun SJ, Wu Y. The role of dexmedetomidine in immune tissue and inflammatory diseases: a narrative review. Eur Rev Med Pharmacol Sci. 2022 Nov 1;26(21).

Gobut H, Erel S, Ozdemir C, Mortas T, Arslan M, Kucuk A, Kasapbasi E, Kavutcu M. Effects of cerium oxide on liver tissue in liver ischemia-reperfusion injury in rats undergoing sevoflurane anesthesia. Exp Ther Med. 2023 Apr 1;25(4):1-8.

?engel N, Köksal Z, Dursun AD, Kurtipek Ö, Sezen ?C, Arslan M, Kavutçu M. Effects of dexmedetomidine administered through different routes on kidney tissue in rats with spinal cord ischemia-reperfusion injury. Drug Des Devel Ther. 2023 Dec 31:2229-39.

Dong A, Zhang Y, Lu S, Yu W. [Retracted] Influence of dexmedetomidine on myocardial injury in patients with simultaneous pancreas-kidney transplantation. Evid Based Complement Alternat Med. 2022;2022:7196449.

Liang H, Liu HZ, Wang HB, Zhong JY, Yang CX, Zhang B. Dexmedetomidine protects against cisplatin-induced acute kidney injury in mice through regulating apoptosis and inflammation. Inflamm Res. 2017 May;66:399-411.

Wo?nica EA, Inglot M, Wo?nica RK, ?ysenko L. Liver dysfunction in sepsis. Adv Clin Exp Med. 2018 Apr 1;27(4).

Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017 Apr;16(4):273-84.

Yeh CH, Hsieh LP, Lin MC, Wei TS, Lin HC, Chang CC, Hsing CH. Dexmedetomidine reduces lipopolysaccharide induced neuroinflammation, sickness behavior, and anhedonia. PLoS One. 2018 Jan 19;13(1).

Li L, Yin H, Zhao Y, Zhang X, Duan C, Liu J, Huang C, Liu S, Yang S, Li X. Protective role of puerarin on LPS/D-Gal induced acute liver injury via restoring autophagy. Am J Transl Res. 2018;10(3):957.

Liu Y, Sheng B, Wang S, Lu F, Zhen J, Chen W. Dexmedetomidine prevents acute kidney injury after adult cardiac surgery: a meta-analysis of randomized controlled trials. BMC Anesthesiol. 2018 Dec;18:1-1.

Downloads

Published

2024-09-30

How to Cite

1.
Shamsa Mohsin, Fatima Inam, Munazza Sardar, Nadia Majeed, Humaira Gul, Rukhsana Jabeen. Study of Histopathology of Rat Liver under the Effects of Dexmedetomidine during Experimental Sepsis. Proceedings S.Z.M.C [Internet]. 2024 Sep. 30 [cited 2024 Oct. 7];38(3):210-3. Available from: https://proceedings-szmc.org.pk/index.php/szmc/article/view/534